Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies. In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.
Study Type
OBSERVATIONAL
Enrollment
500
different treatments based on the molecular analysis
Xiaomin Niu
Shanghai, Shanghai Municipality, China
RECRUITINGObjective response rate (ORR)
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Time frame: 20 years
Disease control rate (DCR)
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Time frame: 20 years
Progression-free survival (PFS)
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Time frame: 20 years
Overall survival (OS)
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Time frame: 20 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.